An investigation on serum antibody level of varicella-zoster virus in healthy population in Beijing.
10.3760/cma.j.cn112150-20211221-01174
- Author:
Luo Dan SUO
1
;
Dan ZHAO
1
;
Meng CHEN
1
;
Juan LI
1
;
Mei DONG
1
;
Yi Ting WANG
1
;
Xia Li YU
1
;
Mao Zhong LI
1
;
Fang HUANG
1
;
Xing Huo PANG
1
;
Li LU
1
Author Information
1. Institute of Immunization and Prevention, Beijing Municipal Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Institute of Immunization and Prevention, Beijing 100013, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Antibodies, Viral;
Chickenpox/prevention & control*;
Chickenpox Vaccine;
Child;
Child, Preschool;
Cross-Sectional Studies;
Female;
Herpesvirus 3, Human;
Humans;
Infant;
Male;
Vaccination
- From:
Chinese Journal of Preventive Medicine
2022;56(2):108-113
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the level and trend of varicella-zoster virus (VZV) antibody among healthy population in Beijing in 2017, after the five-year implementation of the two doses varicella vaccination strategy in 2012, and to provide evidence for scientific evaluation of immunization strategy. Methods: A total of 2 144 subjects in ten age groups from 8 districts of Beijing city were recruited in this study using cross-sectional survey based on multi-stage cluster random sampling method. Serum samples were collected and VZV antibody was detected by ELISA. The influencing factors of antibody concentration and positive rate were analyzed and compared with the study in 2012. The antibody concentration and antibody positive rate were analyzed by nonparametric test and χ² test respectively. Results: The ratio of subjects with registered residence in Beijing city to other provinces was 1∶1. The ratio of male to female was 1∶1.08. The median concentration of VZV antibody was 341.4 (78.6, 1 497.8) mIU/ml, and the total antibody positive rate was 71.1% (1 524/2 144). There were significant differences in antibody positive rate (χ²=736.39, P<0.01) and antibody concentration (χ²=740.34, P<0.01) among different age groups. The antibody positive rate generally increased with age (χ²trend=7.32, Ptrend<0.01). Among 862 children under 14 years old, the antibody positive rate of two doses vaccination 72.8% (182/250) was significantly higher than that of one dose vaccination 51.9% (154/297) (χ²=25.14, P<0.01). There was significant difference between 1-4 years old group (χ²=11.71, P<0.01) and 10-14 years old group (χ²=5.95, P=0.02), but not in 5-9 years old group (χ²=3.00, P=0.07). Compared with the study in 2012, the antibody positive rate increased in 5-9 years old group (χ²=14.35, P<0.01) and decreased in 1-4 years old group (χ²=11.51, P=0.01) in 2017. Conclusion: The recommended varicella booster vaccination has significantly improved the VZV antibody level of children in Beijing city. In the future, it is necessary to explore a more optimized two doses varicella vaccination schedule for children in combination with epidemiological evidence.
